Abstract 129P
Background
Biliary tract cancers (BTC) are classified as gallbladder tumours (GBC) and intrahepatic (iCCA) or perihilar and distal extrahepatic cholangiocarcinomas (eCCA). BTC’s 3-year recurrence rate is up to 80%. Capecitabine (CAP) is the standard for adjuvant (adj) chemotherapy (CT). We collected a retrospective multicentre Italian series of resected BTC and analysed the impact of adj CT on survival.
Methods
Main variables were ECOG performance status (PS), pre-surgical (SUR) Ca 19.9 value, type of SUR, site, histology, invasion (T), nodal status (N), vascular invasion (V) resection margins (R), grade (G). Median follow-up (FU) was estimated with reverse Kaplan-Meier (KM) approach; median RFS (RFS) and median overall survival (OS) were estimated by KM method.
Results
We included 142 all-stages BTC resected from 2005 to 2022, adj CT was given to 69 BTC. With median FU of 89 months (mo), overall RFS and OS were 17 and 30 mo. Lower ECOG PS was associated with longer RFS and OS (p<0.001). A pre-SUR Ca19.9 ≤ 29 was associated with longer RFS in iCCA (p=0.001) and OS both in iCCA (p=0.010) and GBC (p=0.019). Lower T was associated with longer RFS (p=0.002) and OS (p<0.001) in iCCA and GBC but not in eCCA. N0 status correlated with longer RFS in iCCA (p<0.001) and OS both in iCCA and GBC (p<0.006). R0 status was associated with longer RFS in eCCA (p=0.043) and GBC (p<0.001), showing longer OS only in GBC only (p<0.001). V0 status was associated with longer RFS (p=0.017) and OS (p=0.009) in iCCA . Adj CT didn’t impact both on RFS (p=0.539) and OS (p=0.978) in the whole cohort. After stratification by site, eCCA showed an advantage given by adj CT on mRFS (p=0.047). Comparing all adj CT, CAP performed better in iCCA, with a mRFS of 19 mo. Multivariate Cox regression analysis for RFS and OS was stratified for iCCA, eCCA and GBC: ECOG PS, R and N status retained significant correlation with RFS (p<0.001, p<0.001 and p=0.034, respectively) and OS (p<0.001, p<0.001, p=0.013, respectively). Pre-SUR Ca19.9 value correlated with OS (p=0.001).
Conclusions
In our series, adj CT didn’t impact on survival except for eCCA. Evaluation of multiple prognostic variables (including T, N, R and V status and pre-SUR Ca19.9) is necessary to identify a subgroup of BTC that can benefit more from adj CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17